von Groote, Thilo
Albert, Felix
Meersch, Melanie
Koch, Raphael
Porschen, Christian
Hartmann, Oliver
Bergmann, Deborah
Pickkers, Peter
Zarbock, Alexander
Clinical trials referenced in this document:
Documents that mention this clinical trial
Proenkephalin A 119–159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial
https://doi.org/10.1186/s13054-022-04217-4
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (ZA428/18-1, ZA428/18-1, ZA428/18-1)
Westfälische Wilhelms-Universität Münster
Article History
Received: 9 September 2022
Accepted: 14 October 2022
First Online: 31 October 2022
Declarations
:
: The ELAIN trial received ethics approval by the ethics committee of the Ärztekammer Westfalen-Lippe and the medical faculty of the University of Münster, Germany, under the file code 21012-426-f-S (05-AnIt-12). This ethics approval included storage of patient data and biosamples for future research projects. The ELAIN trial was registered in a clinical trial database prior to study start at the German Clinical Trial Registry (Identifier: DRKS00004367).
: All authors read and approved the final manuscript for publication.
: Oliver Hartmann and Deborah Bergmann are employed at SphingoTec GmbH, the company that holds patent rights related to the penKid assay. Peter Pickkers has received consultancy and travel reimbursements from Sphingotec. The other authors declare no competing interest in relation to the study.